Your shopping cart is currently empty

LF3 is a specific inhibitor of canonical Wnt signaling by disrupting the interaction between β-catenin and TCF4 (IC50 < 2 μM)

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 5 mg | $39 | In Stock | In Stock | |
| 10 mg | $65 | In Stock | In Stock | |
| 25 mg | $139 | In Stock | In Stock | |
| 50 mg | $219 | In Stock | In Stock | |
| 100 mg | $328 | In Stock | In Stock | |
| 200 mg | $492 | In Stock | In Stock | |
| 1 mL x 10 mM (in DMSO) | $53 | In Stock | In Stock |
| Description | LF3 is a specific inhibitor of canonical Wnt signaling by disrupting the interaction between β-catenin and TCF4 (IC50 < 2 μM) |
| Targets&IC50 | β-catenin/TCF4 (Alpha Screen):1.65 μM , β-catenin/TCF4 (ELISA):1.82 μM |
| In vitro | LF3 inhibited Wnt/β-catenin signals in cells with exogenous reporters and in colon cancer cells with endogenously high Wnt activity. LF3 also suppressed features of cancer cells related to Wnt signaling, including high cell motility, cell-cycle progression, and the overexpression of Wnt target genes[1]. |
| In vivo | LF3 reduced tumor growth and induced differentiation in a mouse xenograft model of colon cancer.LF3 is a specific inhibitor of canonical Wnt signaling with anticancer activity[1]. |
| Animal Research | Unsorted GFPlow and GFPhigh SW480 cells (1 × 10^4) were subcutaneously injected into the back skin of NOD/SCID mice. Tumor growth was monitored over a period of 45 days. For therapy, LF3 was administered i.v. at 50 mg/kg body weight for three rounds over 5 consecutive days, with 2-day breaks[1]. |
| Molecular Weight | 416.56 |
| Formula | C20H24N4O2S2 |
| Cas No. | 664969-54-4 |
| Smiles | NS(=O)(=O)c1ccc(NC(=S)N2CCN(C\C=C\c3ccccc3)CC2)cc1 |
| Relative Density. | 1.341 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 250 mg/mL (600.15 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (4.8 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.